Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity
Key Takeaways
Acute brain injury transfusion decisions require clinical context; TRAIN and HEMOTION studied different populations and thresholds.
Thrombocytopenia with microangiopathic hemolysis and neurologic abnormalities requires urgent evaluation for TTP and other TMAs.
DIC requires treatment of its cause; blood products address bleeding or procedural needs rather than every abnormal laboratory value.
ICANS after immune effector-cell therapy can include aphasia, seizures, depressed consciousness, and cerebral edema.
Anemia and Oxygen Delivery
Arterial oxygen content depends mainly on hemoglobin concentration and saturation, with a much smaller dissolved oxygen contribution. A normal saturation therefore does not guarantee adequate oxygen delivery in severe anemia. Assess active bleeding, systemic perfusion, myocardial ischemia, cerebral hypoxia, and the adverse effects of transfusion rather than using saturation alone to decide whether anemia is clinically important.
General restrictive transfusion thresholds cannot be treated as a settled universal rule for all acute brain injuries. TRAIN (2024) compared triggers below 9 versus below 7 g/dL in patients with TBI, aSAH, or ICH and favored the liberal strategy for its neurologic outcome. HEMOTION (2024) compared thresholds of 10 versus 7 g/dL in moderate or severe TBI; its primary comparison did not reach statistical significance. These trials differ in populations, thresholds, and outcome methods. Neither proves that every neuro-ICU patient must be transfused to one fixed value.
During transfusion, watch for circulatory overload, hemolysis, allergic reactions, lung injury, electrolyte abnormalities, and infection-related concerns. Sudden respiratory distress can reflect transfusion-associated circulatory overload or other reactions as well as the original disease. Stop and evaluate a suspected serious reaction according to the transfusion protocol.
Platelets, Coagulation, and DIC
A low platelet count may reflect sepsis, consumption, drugs, marrow disease, immune destruction, or laboratory artifact. The safe threshold depends on the procedure and clinical indication. Intracranial surgery often uses a higher target than low-risk bedside procedures. Do not generalize evidence against platelet transfusion in nonsurgical aspirin-associated ICH to every patient with true thrombocytopenic bleeding.
Disseminated intravascular coagulation (DIC) involves systemic coagulation activation with variable consumption and fibrinolysis. Falling platelets, prolonged clotting times, increased fibrin-degradation markers, and low or declining fibrinogen support the diagnosis in the right setting. Fibrinogen may initially be normal or high as an acute-phase reactant. Treat the cause, such as sepsis, trauma, or malignancy. Give platelets, fibrinogen replacement, or plasma for active bleeding or a defined procedural need as appropriate; chasing every abnormal test can cause unnecessary transfusion.
Heparin-induced thrombocytopenia is a prothrombotic immune disorder, not simply bleeding from a low platelet count. Consider the timing, degree of platelet fall, thrombosis, and alternative causes. A sufficiently concerning presentation requires stopping heparin and arranging an appropriate non-heparin strategy with diagnostic testing and specialist input. Intracranial hemorrhage complicates treatment but does not make the thrombosis risk disappear.
Thrombotic Microangiopathies
Microangiopathic hemolytic anemia features fragmented erythrocytes, increased LDH, reduced haptoglobin, and other hemolysis findings. When accompanied by thrombocytopenia and organ injury, consider a thrombotic microangiopathy (TMA). TTP, Shiga toxin-associated HUS, complement-mediated TMA, malignant hypertension, pregnancy syndromes, drugs, and transplant-associated disease have overlapping presentations but different treatments.
| Syndrome | Important clue | Immediate implication |
|---|---|---|
| Immune TTP | Severe ADAMTS13 deficiency, often neurologic involvement | Urgent plasma-exchange and immune-directed pathway when strongly suspected |
| Shiga toxin-associated HUS | Relevant diarrheal illness and renal injury | Supportive and specialist care; do not assume identical therapy to TTP |
| Complement-mediated TMA | Compatible syndrome after alternative causes assessed | Consider complement-directed specialist treatment |
| DIC | Consumptive coagulopathy in a triggering systemic illness | Treat cause and manage bleeding or procedural needs |
Do not wait for the historic full TTP pentad. Draw ADAMTS13 testing before plasma therapy when feasible, but do not delay urgent treatment of a high-probability case. Therapeutic plasma exchange and corticosteroids form core immune-TTP treatment; rituximab and caplacizumab are selected by the treating team. Routine prophylactic platelet transfusion is generally avoided in TTP, with exceptions for life-threatening bleeding or compelling procedures.
Sickle Cell and Acute Neurologic Deficits
Sickle cell disease can cause ischemic stroke, hemorrhage, venous thrombosis, or other neurologic complications. A new deficit or TIA requires immediate stroke evaluation and urgent hematology involvement. ASH recommends prompt transfusion, preferably within two hours of presentation for an acute event in the applicable window; exchange is often preferred when available, with simple transfusion used in selected circumstances. Avoid excessive viscosity from indiscriminately raising hemoglobin. Obtain imaging and assess other standard stroke therapies without delaying the sickle-specific pathway.
Chemotherapy, Stem-Cell Transplantation, and Immune Effector Cells
Treatment-related encephalopathy can reflect direct chemotherapy toxicity, infection, metabolic disturbance, PRES, vascular disease, or immune effector cell-associated neurotoxicity syndrome (ICANS). After stem-cell transplantation, also consider transplant-associated TMA and opportunistic infection. Timeline, medication exposure, organ function, imaging, EEG, and targeted CSF assessment guide differentiation.
ICANS can follow CAR-T or related immune effector therapies. Early language or writing changes, inattention, tremor, seizures, and worsening arousal are important. ASTCT grading uses the ICE assessment together with consciousness, seizures, motor findings, and cerebral edema; the ICE score alone is not the whole grade. Exclude hypoglycemia, infection, stroke, medication effects, and other causes. Severe cases need ICU monitoring, EEG, appropriate corticosteroid therapy, and management of seizures or edema under the cellular-therapy protocol.
Cytokine release syndrome (CRS) can coexist and has a distinct treatment pathway. Tocilizumab is used for appropriate CRS but should not be portrayed as adequate sole therapy for isolated ICANS. Discuss treatment with the oncology or cellular-therapy team promptly. Immune checkpoint inhibitors can also cause encephalitis, myositis, neuropathy, and overlapping myasthenia–myositis–myocarditis; respiratory weakness or cardiac abnormalities warrant urgent multisystem evaluation.
Sources checked October 17, 2026: TRAIN, HEMOTION, ISTH TTP statements, ASTCT grading consensus, and ASH cerebrovascular guidance.
Thrombocytopenia, schistocytes, hemolysis, and fluctuating focal deficits raise strong concern for immune TTP. What is appropriate?
Urgently involve hematology, obtain ADAMTS13 testing if feasible, and initiate the indicated plasma-exchange pathway without an avoidable delay
Wait for all five historic pentad findings
Give routine prophylactic platelets as the only therapy
Exclude TTP because renal failure is not severe
Which statement about ICANS is correct?
The ICE score alone defines all severity
Language change, seizures, arousal, motor findings, and edema require a structured assessment with competing causes excluded
Tocilizumab alone is sufficient for isolated ICANS
All neurologic symptoms after CAR-T prove ICANS without differential diagnosis
Sections you finish are checked off in the contents.